#TSX #Mining #Stocks $BRZ.V, $MCI.V, $ORG.V, $SSS.V
Added to #Investorideas
Investorideas Sector
Updates in #Mining, #Biotech and #Water #Stocks
Point Roberts, WA, Delta BC – October 28, 2016 –
Investorideas.com, a global news source and investor resource covering actively
traded sectors announces this week’s additions to its growing global stock
directories within the mining, biotech and water sectors.
All new mining stocks are Canadian-based and listed
on the TSX Venture Exchange.
This week’s water stocks list addition is Forterra,
Inc. (NasdaqGM:FRTA), a manufacturer of pipe and pre-cast products used in a
variety of water-related infrastructure applications.
New biotech stocks include a biotherapeutics
company currently working on hypertension therapies, a clinical stage
biotechnology company focused on rare genetic diseases, a molecular diagnostics
company, an imaging company focused on early cancer detection and a
solutions/service provider for the pharmaceutical market.
Mining Companies Added:
Bearing Resources Ltd. (TSX:
BRZ.V), Minnova Corp. (TSX: MCI.V), Orca
Gold Inc. (TSX:ORG.V)
and Sunvest Minerals
Corp. (TSX: SSS.V)
Water Companies Added:
Forterra,
Inc. (NasdaqGM:FRTA) is a manufacturer of pipe and precast
products in the U.S. and Eastern Canada for a variety of water-related
infrastructure applications, including water transmission, distribution and
drainage. Based in Irving, Texas, Forterra employs more than 5,500 people and
operates more than 95 facilities, with products available throughout the U.S.
and Eastern Canada.
Biotech/Life Sciences Companies
Added:
Bellerophon
Therapeutics LLC (NasdaqGM: BLPH) is a clinical-stage biotherapeutics
company focused on developing innovative therapies at the intersection of drugs
and devices that address significant unmet medical needs in the treatment of
cardiopulmonary diseases. The Company is currently developing three product
candidates under its INOpulse program, a proprietary pulsatile nitric oxide
delivery device. The first is for the treatment of pulmonary arterial
hypertension (PAH), for which the Company has commenced Phase 3 clinical trials
in 2016. The second is for the treatment of pulmonary hypertension associated
with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is
for the treatment of pulmonary hypertension associated with Idiopathic
Pulmonary Fibrosis (PH-IPF) both of which are in Phase 2 development. The
Company’s plans call for the completion of further work on the use of INOpulse
to treat PH-COPD and PH-IPF during 2016.
Bio Blast Pharma Ltd. (NasdaqGM: ORPN) is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases, with a lead drug candidate -- trehalose 90mg/mL IV solution -- in Phase 2 development. Bioblast was founded in 2012.
AlliancePharma Inc. (TSX:APA.V) is a leading solution and service provider to the
pharmaceutical market. Today it is a respected name for quality and expertise
among pharmacists. Its management team is guided by a vision of continuing to
lead the way in Quebec while extending operations across Canada and
internationally.
Biocartis Group NV (Brussels: BCART.BR) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis` proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis has five oncology tests and two infectious disease tests.
Imagin Medical Inc.
(CSE:IME,
OTC:IMEXF,
Frankfurt:DPD2.F) is developing imaging solutions for the early
detection of cancer through the use of endoscopes. The Company believes it will
radically improve the way physicians detect cancer. Imagin’s initial target
market is bladder cancer, a major cancer worldwide, the sixth most prevalent in
the U.S., and the most costly cancer to treat due to a greater than 50%
recurrence rate. Developed at the Lawrence Livermore National Laboratory, this
advanced, ultrasensitive imaging technology is based upon improved optical
designs and advanced light sensors.
Investorideas.com global stock directories are part
of the membership program on the site, accessed either by login and password or
available in PDF format. The directories
include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized
global stock exchanges, giving retail investors a wide variety of stocks to
review. http://www.investorideas.com/membership/
The directories are not meant as recommendations
but as a research tool to discover opportunities and trading ideas in a
particular sector.
About Investorideas.com - News that Inspires Big Ideas
Sectors we cover in include mining, energy,
renewable energy, water stocks, food and beverage (including organic and LOHAS,
wine), defense and security, biotech, technology and mobile. We have also
expanded our global coverage to include Latin American stocks, the Middle East,
sports and entertainment.
Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks,
renewable energy, nanotech, defense, technology, biotech and more – use our
stock directories and access them online 24/7 with login as a member to find
your next big idea!
Disclaimer/Disclosure:
Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global
Investors: Effective September 15 2008 - all BC investors should review all OTC
and Pink sheet listed companies for adherence in new disclosure filings and
filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to
regulations of each country.
Contact Investorideas.com
800-665-0411
